UK Promises Reduced Trial Burden For Biosimilars

MHRA Sets Out Plans For ‘Innovative’ Procedure After EU Transition

 
• By Dave Wallace

New UK licensing procedures for biosimilars are about to be set out by the MHRA that will reduce the clinical trial data burden for applicants.

Heavy box
The MHRA is planning to reduce the trial burden for biosimilars • Source: Shutterstock

More from Regulation

More from Policy & Regulation